1. Home
  2. BEAM vs RPD Comparison

BEAM vs RPD Comparison

Compare BEAM & RPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • RPD
  • Stock Information
  • Founded
  • BEAM 2017
  • RPD 2000
  • Country
  • BEAM United States
  • RPD United States
  • Employees
  • BEAM N/A
  • RPD N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • RPD Computer Software: Prepackaged Software
  • Sector
  • BEAM Health Care
  • RPD Technology
  • Exchange
  • BEAM Nasdaq
  • RPD Nasdaq
  • Market Cap
  • BEAM 2.3B
  • RPD 2.5B
  • IPO Year
  • BEAM 2020
  • RPD 2015
  • Fundamental
  • Price
  • BEAM $30.43
  • RPD $31.71
  • Analyst Decision
  • BEAM Buy
  • RPD Buy
  • Analyst Count
  • BEAM 10
  • RPD 20
  • Target Price
  • BEAM $48.75
  • RPD $41.94
  • AVG Volume (30 Days)
  • BEAM 1.2M
  • RPD 801.7K
  • Earning Date
  • BEAM 03-04-2025
  • RPD 02-12-2025
  • Dividend Yield
  • BEAM N/A
  • RPD N/A
  • EPS Growth
  • BEAM N/A
  • RPD N/A
  • EPS
  • BEAM N/A
  • RPD 0.40
  • Revenue
  • BEAM $349,643,000.00
  • RPD $844,007,000.00
  • Revenue This Year
  • BEAM N/A
  • RPD $5.90
  • Revenue Next Year
  • BEAM $14.62
  • RPD $6.52
  • P/E Ratio
  • BEAM N/A
  • RPD $79.05
  • Revenue Growth
  • BEAM 328.73
  • RPD 8.53
  • 52 Week Low
  • BEAM $20.84
  • RPD $31.52
  • 52 Week High
  • BEAM $49.50
  • RPD $59.43
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 57.12
  • RPD 19.89
  • Support Level
  • BEAM $25.35
  • RPD $33.70
  • Resistance Level
  • BEAM $35.25
  • RPD $38.98
  • Average True Range (ATR)
  • BEAM 2.10
  • RPD 1.36
  • MACD
  • BEAM 0.56
  • RPD -0.61
  • Stochastic Oscillator
  • BEAM 55.88
  • RPD 2.41

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.

About RPD Rapid7 Inc.

Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.

Share on Social Networks: